Home/Pipeline/AP-PA02

AP-PA02

Pseudomonas aeruginosa infections in cystic fibrosis

Phase 1b/2aActive

Key Facts

Indication
Pseudomonas aeruginosa infections in cystic fibrosis
Phase
Phase 1b/2a
Status
Active
Company

About Armata Pharmaceuticals

Armata Pharmaceuticals is a clinical-stage biotech focused on developing pathogen-specific bacteriophage therapeutics to treat antibiotic-resistant infections, a critical global health threat. The company's core strategy is built on a vertically integrated platform that spans from natural phage discovery and synthetic engineering to in-house cGMP manufacturing and clinical development. Its lead programs target high-mortality infections like Pseudomonas aeruginosa in cystic fibrosis and Staphylococcus aureus bacteremia, aiming to provide a precise alternative to broad-spectrum antibiotics. Armata's fully controlled 56,000 sq. ft. facility in Los Angeles provides a strategic advantage in developing these complex biologic products.

View full company profile

Other Pseudomonas aeruginosa infections in cystic fibrosis Drugs

DrugCompanyPhase
CSA-131 (Kinnear Pharma)N8 MedicalPre-clinical/Research